公开(公告)号：US20240352002A1

公开(公告)日：2024-10-24

申请号：US18035262

申请日：2021-11-18

Applicant: Curasen Therapeutics, Inc.

Inventor： Jiaxin Yu ,  David Scott Carter ,  Anthony P. Ford ,  Wei Chen

IPC: C07D403/06 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D205/04 ,  C07D207/08 ,  C07D213/30 ,  C07D213/73 ,  C07D213/84 ,  C07D239/42 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

CPC classification number: C07D403/06 ,  A61K31/397 ,  A61K31/4035 ,  A61K31/422 ,  A61K31/427 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/55 ,  C07D205/04 ,  C07D207/08 ,  C07D213/30 ,  C07D213/73 ,  C07D213/84 ,  C07D239/42 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor. Disclosed herein is a compound according to Formula (I) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof. Further disclosed herein is a compound according to Formula (II) or an optically pure stereoisomer, pharmaceutically acceptable salt, solvate, or prodrug thereof.

公开(公告)号：US20240343717A1

公开(公告)日：2024-10-17

申请号：US18294191

申请日：2022-07-28

Applicant: SYNGENTA CROP PROTECTION AG

Inventor： Andrew EDMUNDS ,  Christopher Charles SCARBOROUGH ,  Simon WILLIAMS ,  Pierre Joseph Marcel JUNG ,  Peter FINKBEINER ,  Martin POULIOT ,  Daria GROSHEVA ,  Lars SUESSE ,  Guillaume BRUNOT ,  Damien BONVALOT

IPC: C07D413/14 ,  A01N43/80 ,  A01N43/82 ,  A01P3/00 ,  C07D401/06 ,  C07D403/06 ,  C07D417/14

CPC classification number: C07D413/14 ,  A01N43/80 ,  A01N43/82 ,  A01P3/00 ,  C07D401/06 ,  C07D403/06 ,  C07D417/14

Abstract: A compound of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as fungicides.

公开(公告)号：US20240327387A1

公开(公告)日：2024-10-03

申请号：US18570282

申请日：2022-06-23

Applicant: UNIVERSITA' DEGLI STUDI DI MILANO

Inventor： Luciana Marinelli ,  Daniela Arosio ,  Pierfausto Seneci

IPC: C07D403/12 ,  A61K45/06 ,  A61K49/00 ,  C07D251/46 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/12 ,  C07D495/04

CPC classification number: C07D403/12 ,  A61K45/06 ,  A61K49/0021 ,  C07D251/46 ,  C07D401/06 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/12 ,  C07D495/04

Abstract: The present invention relates to compounds of Formula (I) to their pharmaceutical composition and their use as a medicament, in particular for the treatment and/or prevention of a tumour, viral infection, bacterial infection or neurodegenerative disease.

公开(公告)号：US20240317686A1

公开(公告)日：2024-09-26

申请号：US18270664

申请日：2021-12-29

Applicant: SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.

Inventor： Qian Wang ,  Bingbin Zhang ,  Guangxin Xia ,  Sijie Shu ,  Guoyong Huo ,  Zhijun Xiang ,  Guosheng Wu ,  Tao Liang ,  Chen Shi ,  Yongxin Zhao ,  Lingwen Li ,  Ying Ke

IPC: C07D213/75 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  C07D403/06 ,  C07D413/06 ,  C07D417/06

CPC classification number: C07D213/75 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/506 ,  C07D403/06 ,  C07D413/06 ,  C07D417/06

Abstract: Provided are an RORγt modulator, and a preparation method therefor and an application thereof. The RORγt modulator is selected from a compound represented by formula I, and a pharmaceutically acceptable salt, solvate, solvate of pharmaceutically acceptable salt, metabolite or prodrug thereof. The compound has inhibitory activity on RORγt, and can effectively inhibit an RORγt protein receptor, thereby regulating the differentiation of Th17 cells, inhibiting generation of IL-17, and then treating RORγt-mediated relevant autoimmune diseases.

公开(公告)号：US20240287041A1

公开(公告)日：2024-08-29

申请号：US18561374

申请日：2022-05-20

Applicant: Karyopharm Therapeutics Inc.

Inventor： Erkan Baloglu ,  Brian C. Austad ,  David G. Roe ,  Andrew Keduc ,  Stephen Edmund Gottschling ,  Evan Hecker

IPC: C07D403/06 ,  A61K31/506

CPC classification number: C07D403/06 ,  A61K31/506

Abstract: The present invention relates to a method of preparing a compound represented by structural formula (VII), comprising reacting a compound represented by structural formula (II), with a compound represented by structural formula (III), in a solvent, in the presence of a Pd catalyst and one or more inorganic bases under conditions suitable to prepare a compound represented by structural formula (VII): The values and example values of the variables in structural formulas (VII), (II), and (III) are defined herein. The present invention also relates to crystalline Forms I and II of the compound represented by Structural Formula (VII), the use of the crystalline Forms in treating disease or disorders associated with CRM1 and method of preparing the crystalline Forms.

公开(公告)号：US12065405B2

公开(公告)日：2024-08-20

申请号：US18299347

申请日：2023-04-12

Applicant: ATAI Therapeutics, Inc.

Inventor： Robert B. Perni ,  Glenn Short ,  Srinivas G. Rao ,  Tanweer A. Khan

IPC: C07D209/16 ,  C07D209/08 ,  C07D209/12 ,  C07D209/14 ,  C07D401/06 ,  C07D403/06 ,  C07F9/572

CPC classification number: C07D209/16 ,  C07D209/08 ,  C07D209/12 ,  C07D209/14 ,  C07D401/06 ,  C07D403/06 ,  C07F9/5728

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W, and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

公开(公告)号：US12054504B2

公开(公告)日：2024-08-06

申请号：US17879320

申请日：2022-08-02

Applicant: Mindset Pharma Inc.

Inventor： Abdelmalik Slassi ,  Joseph Araujo

IPC: A61K31/675 ,  C07D403/06 ,  C07F9/572

CPC classification number: C07F9/5728 ,  C07D403/06 ,  A61K31/675 ,  C07B2200/05 ,  A61K31/404 ,  A61K2300/00 ,  A61K31/675 ,  A61K2300/00 ,  A61K31/454 ,  A61K2300/00

Abstract: The present application relates to 3-cyclic amine-indole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptor in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptor in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses, and other neurological diseases, disorders and conditions.

公开(公告)号：US20240246908A1

公开(公告)日：2024-07-25

申请号：US18555291

申请日：2022-04-14

Applicant: ORION CORPORATION

Inventor： Marko AHLMARK ,  David DIN BELLE ,  Dimitris NOUTSIAS ,  Pekka PIETIKÄINEN ,  Petteri RUMMAKKO ,  Julius SIPILÄ ,  Gerd WOHLFAHRT

IPC: C07D207/277 ,  A61K31/197 ,  A61K31/381 ,  A61K31/382 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/407 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/4166 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/427 ,  A61K31/429 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/45 ,  A61K31/4525 ,  A61K31/453 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/496 ,  C07C237/04 ,  C07D205/04 ,  C07D205/08 ,  C07D207/16 ,  C07D207/24 ,  C07D207/263 ,  C07D211/78 ,  C07D213/81 ,  C07D233/32 ,  C07D257/04 ,  C07D263/24 ,  C07D275/03 ,  C07D285/00 ,  C07D333/48 ,  C07D335/02 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D487/04 ,  C07D513/04

CPC classification number: C07D207/277 ,  A61K31/197 ,  A61K31/381 ,  A61K31/382 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4025 ,  A61K31/407 ,  A61K31/41 ,  A61K31/4155 ,  A61K31/4166 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/427 ,  A61K31/429 ,  A61K31/4412 ,  A61K31/4439 ,  A61K31/45 ,  A61K31/4525 ,  A61K31/453 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/495 ,  A61K31/496 ,  C07C237/04 ,  C07D205/04 ,  C07D205/08 ,  C07D207/16 ,  C07D207/24 ,  C07D207/263 ,  C07D211/78 ,  C07D213/81 ,  C07D233/32 ,  C07D257/04 ,  C07D263/24 ,  C07D275/03 ,  C07D285/00 ,  C07D333/48 ,  C07D335/02 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/06 ,  C07D403/12 ,  C07D405/04 ,  C07D405/12 ,  C07D405/14 ,  C07D413/12 ,  C07D487/04 ,  C07D513/04

Abstract: The present invention relates to a compound of formula (I)






wherein A, Z, L, R1, R2, R3, R4, R5 and R33 are as defined in claim 1, or a pharmaceutically acceptable salt thereof. The compounds of formula (I) possess utility as inhibitors of TEAD. The compounds are useful as medicaments in the treatment of diseases or conditions wherein inhibition of TEAD is desired, such as cancer and chronic pain.

公开(公告)号：US20240238281A1

公开(公告)日：2024-07-18

申请号：US18557580

申请日：2022-04-22

Applicant: GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD. BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY ,  MEDSHINE DISCOVERY INC.

Inventor： Jiansong WANG ,  Zhibo LUO ,  Fei QIN ,  Wei WEI ,  Zhigan JIANG ,  Zhixiang PAN ,  Yingxia BAO ,  Haiying HE ,  Haiwen HUANG ,  Shuhui CHEN

IPC: A61K31/496 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14

CPC classification number: A61K31/496 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D405/14

Abstract: A class of piperazine derivatives and application thereof, specifically compound represented by formula (III) or pharmaceutically acceptable salt thereof.

公开(公告)号：US20240228456A1

公开(公告)日：2024-07-11

申请号：US18557827

申请日：2022-06-13

Applicant: JOHNSON MATTHEY PUBLIC LIMITED COMPANY

Inventor： Johannes SCHRANCK ,  Eric SLACK

IPC: C07D401/06 ,  C07C1/207 ,  C07C41/30 ,  C07C253/30 ,  C07D213/24 ,  C07D277/22 ,  C07D307/36 ,  C07D333/10 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D417/06

CPC classification number: C07D401/06 ,  C07C1/2078 ,  C07C41/30 ,  C07C253/30 ,  C07D213/24 ,  C07D277/22 ,  C07D307/36 ,  C07D333/10 ,  C07D403/06 ,  C07D405/06 ,  C07D409/06 ,  C07D417/06

Abstract: The invention relates to a process for synthesising organic molecules. The invention provides a process for forming an sp2-sp3 carbon-carbon bond between a first compound comprising a substituted or unsubstituted aromatic group and a second compound comprising a substituted or unsubstituted aromatic group in the presence of a catalyst, water, and a first base. The process may find use in the preparation of active pharmaceutical ingredients.